Mixtures of viruses that attack inflammatory bowel disease–causing bacteria in mice also survive the digestive tract and are well-tolerated in humans, a study finds.
Neil S. Greenspan and Arturo Casadevall | Nov 1, 2019 | 3 min read
Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.
In Chapter 3, “The Enemy of Our Enemy Is Our Friend: Infecting the Infection,” author Emily Monosson makes the case for bacteriophage therapy in the treatment of infectious disease.
Phage therapy to combat bacterial infections is garnering attention for the second time in 100 years, but solid clinical support for its widespread use is still lacking.
Researchers develop a CRISPR-based, two-phage system that sensitizes resistant bacteria to antibiotics and selectively kills any remaining drug-resistant bugs.